Biolinerx Ltd. (BLRX) 0.80 $BLRX
BioLineRx's BL-8040 to be Presented at Upcoming Scientific Conferences
PR Newswire - Thu May 19, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that BL-8040, its lead platform for the treatment of multiple cancer and hematological indications, will be presented at two upcoming scientific conferences.
BLRX: 0.80 (-0.01)
BioLineRx Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 17, 7:04AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the first quarter ended March 31, 2016.
BLRX: 0.80 (-0.01)
BioLineRx and MaRS Innovation Sign Framework Collaboration Agreement
PR Newswire - Mon May 16, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS Innovation, the commercialization agent for fifteen of Toronto's top academic institutions. Under the terms of the agreement, BioLineRx intends to review innovative projects and assets of startup companies originating from MaRS Innovation's members, in order to identify in-licensing, co-development or other partnering opportunities.
BLRX: 0.80 (-0.01)
BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016
PR Newswire - Tue Apr 19, 7:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that detailed results from a study on the underlying mechanism of action of BL-8040, its lead platform for the treatment of multiple cancer and hematological indications, were presented by Prof. Amnon Peled at the American Association of Cancer Research (AACR) 2016 meeting in New Orleans.
BLRX: 0.80 (-0.01)
BioLineRx's Novel Treatment for Non-Surgical Removal of Skin Lesions Receives CE Mark Approval
PR Newswire - Mon Apr 04, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that its partner, Omega Pharma, now part of Perrigo, has received CE Mark approval for BL-5010 as a novel OTC treatment for the non-surgical removal of skin lesions. The product's commercial launch by Omega Pharma is expected by mid-2016. Subject to the terms of the licensing agreement with Omega Pharma, BioLineRx plans to provide updates at a later stage regarding the commercial potential of the product and its contribution to the Company's ongoing business.
PRGO: 93.67 (-0.06), BLRX: 0.80 (-0.01)
Best Stocks to Buy Today Wednesday March 23, 2016
ACCESSWIRE - Wed Mar 23, 11:33AM CDT
MIAMI, FL / ACCESSWIRE / March 23, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. SXE, GALE, CPXX, and BLRX have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
CPXX: 30.24 (unch), SXE: 2.01 (+0.02), GALE: 0.46 (unch), BLRX: 0.80 (-0.01)
BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment
PR Newswire - Wed Mar 23, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE:BLRX) announced today the initiation of a Phase 2 trial for BL-8040 as a novel approach for the mobilization and collection of bone marrow stem cells from the peripheral blood circulation.
BLRX: 0.80 (-0.01)
Biotechs in the News
ACCESSWIRE - Mon Mar 21, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 21, 2016 / The past few weeks have been exciting for biotechnology stocks and this week see no difference. Several biotechs have disclosed news this week that has the market reacting favorably. Here are a few stocks you should take an immediate look at:
CPXX: 30.24 (unch), INO: 9.12 (+0.01), CMRX: 3.93 (-0.06), ORPN: 1.64 (-0.03), BLRX: 0.80 (-0.01)
Four Companies Added To Today's Stock Watchlist on Tuesday March 15, 2016
ACCESSWIRE - Tue Mar 15, 9:47AM CDT
MIAMI, FL / ACCESSWIRE / March 15, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. BLRX, OREX, SZYM, and ESI have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
OREX: 0.40 (-0.04), ESI: 2.04 (+0.07), BLRX: 0.80 (-0.01), SZYM: 2.15 (+0.02)
BioLineRx Reports Year End 2015 Financial Results
PR Newswire - Thu Mar 10, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2015.
BLRX: 0.80 (-0.01)
BioLineRx to Present at 2016 Annual Roth Conference in Southern California on March 14
PR Newswire - Thu Mar 10, 5:00AM CST
BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will present a company update at the 28th Annual Roth Conference on Monday, March 14, 2016 at 3:00 pm PST. The conference will be held at the Ritz Carlton in Dana Point, CA.
BLRX: 0.80 (-0.01)
BioLineRx to Report Annual 2015 Results on March 10, 2016
PR Newswire - Thu Mar 03, 6:00AM CST
BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its audited annual financial results for the year ended December 31, 2015 on Thursday, March 10, 2016, before the US markets open.
BLRX: 0.80 (-0.01)
BioLineRx Receives Confirmation of Medical Device Classification in Europe for Celiac Treatment
PR Newswire - Mon Jan 25, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received confirmation from the European Notified Body regarding the classification of BL-7010, a novel polymer for the treatment of celiac disease, as a Class IIb medical device in the European Union.
BLRX: 0.80 (-0.01)
BioLineRx to Present at Biotech Showcase 2016 Conference in San Francisco
PR Newswire - Mon Jan 04, 6:00AM CST
BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the Biotech Showcase 2016 Conference being held in San Francisco, CA.
BLRX: 0.80 (-0.01)
BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Stem Cell Mobilization Treatment
BusinessWire - Mon Dec 14, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of regulatory submissions required to commence a Phase 2 trial for BL-8040 as a novel approach for mobilization and collection of bone marrow stem cells from the peripheral blood circulation. The trial is expected to commence shortly after receipt of regulatory approval, anticipated in the first quarter of 2016.
BLRX: 0.80 (-0.01)
Bioline RX (BLRX) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Fri Dec 04, 8:37AM CST
As of late, it has definitely been a great time to be an investor in Bioline RX Ltd (BLRX)
BLRX: 0.80 (-0.01)
BioLineRx Establishes Oncology Scientific Advisory Board
BusinessWire - Thu Dec 03, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported the establishment of a Scientific Advisory Board (SAB) to provide insight and guidance on the Company's activities in the field of oncology.
BLRX: 0.80 (-0.01)
BioLineRx (BLRX) Worth Watching: Stock Rises 11.3%
Zacks Equity Research - Zacks Investment Research - Wed Dec 02, 7:00AM CST
BioLineRx (BLRX) was a big mover last session, with its shares rising over 11% on the day.
CORT: 6.02 (+0.01), BLRX: 0.80 (-0.01)
BioLineRx Ltd. to Host Investor Breakfast in New York on December 3, 2015
BusinessWire - Wed Nov 25, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it will host an investor breakfast on Thursday, December 3, 2015, in New York City.
BLRX: 0.80 (-0.01)
BioLineRx's BL-8040 to be Presented at Upcoming Scientific Conferences
PR Newswire - Thu May 19, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that BL-8040, its lead platform for the treatment of multiple cancer and hematological indications, will be presented at two upcoming scientific conferences.
BLRX: 0.80 (-0.01)
BioLineRx Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 17, 7:04AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the first quarter ended March 31, 2016.
BLRX: 0.80 (-0.01)
BioLineRx and MaRS Innovation Sign Framework Collaboration Agreement
PR Newswire - Mon May 16, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS Innovation, the commercialization agent for fifteen of Toronto's top academic institutions. Under the terms of the agreement, BioLineRx intends to review innovative projects and assets of startup companies originating from MaRS Innovation's members, in order to identify in-licensing, co-development or other partnering opportunities.
BLRX: 0.80 (-0.01)
BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016
PR Newswire - Tue Apr 19, 7:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that detailed results from a study on the underlying mechanism of action of BL-8040, its lead platform for the treatment of multiple cancer and hematological indications, were presented by Prof. Amnon Peled at the American Association of Cancer Research (AACR) 2016 meeting in New Orleans.
BLRX: 0.80 (-0.01)
BioLineRx's Novel Treatment for Non-Surgical Removal of Skin Lesions Receives CE Mark Approval
PR Newswire - Mon Apr 04, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced today that its partner, Omega Pharma, now part of Perrigo, has received CE Mark approval for BL-5010 as a novel OTC treatment for the non-surgical removal of skin lesions. The product's commercial launch by Omega Pharma is expected by mid-2016. Subject to the terms of the licensing agreement with Omega Pharma, BioLineRx plans to provide updates at a later stage regarding the commercial potential of the product and its contribution to the Company's ongoing business.
PRGO: 93.67 (-0.06), BLRX: 0.80 (-0.01)
Best Stocks to Buy Today Wednesday March 23, 2016
ACCESSWIRE - Wed Mar 23, 11:33AM CDT
MIAMI, FL / ACCESSWIRE / March 23, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. SXE, GALE, CPXX, and BLRX have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
CPXX: 30.24 (unch), SXE: 2.01 (+0.02), GALE: 0.46 (unch), BLRX: 0.80 (-0.01)
BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment
PR Newswire - Wed Mar 23, 6:00AM CDT
BioLineRx Ltd. (NASDAQ/TASE:BLRX) announced today the initiation of a Phase 2 trial for BL-8040 as a novel approach for the mobilization and collection of bone marrow stem cells from the peripheral blood circulation.
BLRX: 0.80 (-0.01)
Biotechs in the News
ACCESSWIRE - Mon Mar 21, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 21, 2016 / The past few weeks have been exciting for biotechnology stocks and this week see no difference. Several biotechs have disclosed news this week that has the market reacting favorably. Here are a few stocks you should take an immediate look at:
CPXX: 30.24 (unch), INO: 9.12 (+0.01), CMRX: 3.93 (-0.06), ORPN: 1.64 (-0.03), BLRX: 0.80 (-0.01)
Four Companies Added To Today's Stock Watchlist on Tuesday March 15, 2016
ACCESSWIRE - Tue Mar 15, 9:47AM CDT
MIAMI, FL / ACCESSWIRE / March 15, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. BLRX, OREX, SZYM, and ESI have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
OREX: 0.40 (-0.04), ESI: 2.04 (+0.07), BLRX: 0.80 (-0.01), SZYM: 2.15 (+0.02)
BioLineRx Reports Year End 2015 Financial Results
PR Newswire - Thu Mar 10, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2015.
BLRX: 0.80 (-0.01)
BioLineRx to Present at 2016 Annual Roth Conference in Southern California on March 14
PR Newswire - Thu Mar 10, 5:00AM CST
BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will present a company update at the 28th Annual Roth Conference on Monday, March 14, 2016 at 3:00 pm PST. The conference will be held at the Ritz Carlton in Dana Point, CA.
BLRX: 0.80 (-0.01)
BioLineRx to Report Annual 2015 Results on March 10, 2016
PR Newswire - Thu Mar 03, 6:00AM CST
BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its audited annual financial results for the year ended December 31, 2015 on Thursday, March 10, 2016, before the US markets open.
BLRX: 0.80 (-0.01)
BioLineRx Receives Confirmation of Medical Device Classification in Europe for Celiac Treatment
PR Newswire - Mon Jan 25, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received confirmation from the European Notified Body regarding the classification of BL-7010, a novel polymer for the treatment of celiac disease, as a Class IIb medical device in the European Union.
BLRX: 0.80 (-0.01)
BioLineRx to Present at Biotech Showcase 2016 Conference in San Francisco
PR Newswire - Mon Jan 04, 6:00AM CST
BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the Biotech Showcase 2016 Conference being held in San Francisco, CA.
BLRX: 0.80 (-0.01)
BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Stem Cell Mobilization Treatment
BusinessWire - Mon Dec 14, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of regulatory submissions required to commence a Phase 2 trial for BL-8040 as a novel approach for mobilization and collection of bone marrow stem cells from the peripheral blood circulation. The trial is expected to commence shortly after receipt of regulatory approval, anticipated in the first quarter of 2016.
BLRX: 0.80 (-0.01)
Bioline RX (BLRX) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Fri Dec 04, 8:37AM CST
As of late, it has definitely been a great time to be an investor in Bioline RX Ltd (BLRX)
BLRX: 0.80 (-0.01)
BioLineRx Establishes Oncology Scientific Advisory Board
BusinessWire - Thu Dec 03, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported the establishment of a Scientific Advisory Board (SAB) to provide insight and guidance on the Company's activities in the field of oncology.
BLRX: 0.80 (-0.01)
BioLineRx (BLRX) Worth Watching: Stock Rises 11.3%
Zacks Equity Research - Zacks Investment Research - Wed Dec 02, 7:00AM CST
BioLineRx (BLRX) was a big mover last session, with its shares rising over 11% on the day.
CORT: 6.02 (+0.01), BLRX: 0.80 (-0.01)
BioLineRx Ltd. to Host Investor Breakfast in New York on December 3, 2015
BusinessWire - Wed Nov 25, 6:00AM CST
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it will host an investor breakfast on Thursday, December 3, 2015, in New York City.
BLRX: 0.80 (-0.01)
